Here's how phar­ma com­pa­nies might re­move their prod­ucts from price ne­go­ti­a­tion

Sev­er­al of the drugs on the list of 10 that will face price ne­go­ti­a­tions may not ac­tu­al­ly end up on the list, thanks to up­com­ing gener­ic and biosim­i­lar com­pe­ti­tion or tac­tics that com­pa­nies may use to speed com­pe­ti­tion.

Of the 10 drugs on CMS’ list, at least four so far —John­son & John­son’s Ste­lara, No­var­tis’ En­tresto, Am­gen’s En­brel and No­vo Nordisk’s in­sulins — may not see ne­go­ti­a­tions in 2026 due to in­com­ing gener­ic or biosim­i­lar com­pe­ti­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.